Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5708922 | 0.87 | POLG (0.48) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL6141746 | 0.86 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL25396644 | 0.85 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL585724 | 0.85 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL17215886 | 0.85 | POLG (0.51) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL30134674 | 0.84 | POLG (0.46) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL6038233 | 0.84 | POLG (0.50) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL10900419 | 0.83 | POLG (0.49) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL27451032 | 0.83 | POLG (0.49) | POLGP2RY2P2RY6P2RY4POLB | |
| SCHEMBL14913974 | 0.82 | P2RY6 (0.57) | P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2535423-B1 | Labeling and detection of nucleic acids | LIFE TECHNOLOGIES CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-20140336079-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | LIFE TECHNOLOGIES CORP (US) | 2014-11-13 | — | — | US | disclosed |
| EP-2535423-A2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2224013-B1 | Methods for the determination of telomerase activity using click chemistry | LIFE TECHNOLOGIES CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8114636-B2 | Labeling and detection of nucleic acids | Life Technologies Corporation (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | Life Technologies Corporation (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2224013-A1 | Methods for the determination of telomerase activity using click chemistry | Life Technologies Corporation (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20080050731-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | INVITROGEN CORPORATION (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261181-A1 | LABELING AND DETECTION OF NUCLEIC ACIDS | RNGTT, ADAR, ALKBH1 | POLG 762/4885P2RY2 2947/4885P2RY6 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.